4SCAR19U T Cells Targeting B Cell Malignancies

Summary

The purpose of this study is to assess the feasibility, safety and efficacy of universal CAR T cell therapy against CD19-positive hematological malignancies using a novel CD19-specific CAR T cell product, 4SCAR19U T cells. The study also aims to learn more about the function of the 4SCAR19U T cells and their persistence in patients. This is a phase I trial enrolling patients from multiple clinical centers.

Timeline

Start

2026-06-01

Primary completion

2029-12-31

Completion

2030-12-31

Drugs

Indications